Physician profile
Sanjay Kumar Emandi
NPI 1275532095
$911.56
in general payments reported to CMS, 2019-2025
24 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.84 · 2021: $23.93 · 2022: $78.88 · 2023: $142 · 2024: $392 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $130.82 | 2023-2025 | Enhertu, Lynparza |
| Lilly USA, LLC | $92.08 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $87.08 | 2023-2025 | Keytruda |
| Abbvie INC. | $76.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.45 | 2024-2025 | Fruzaqla, Iclusig |
| Aveo Pharmaceuticals, INC. | $51.65 | 2024 | |
| Sobi, INC | $43.68 | 2023-2024 | |
| Janssen Biotech, INC. | $36.22 | 2022-2025 | Rybrevant |
| Rigel Pharmaceuticals, INC. | $35.36 | 2022-2024 | Tavalisse, Rezlidhia |
| Astellas Pharma US INC | $34.45 | 2024-2025 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $24.93 | 2022 | |
| Geron Corporation | $24.15 | 2025 | Rytelo |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Pfizer INC. | $23.76 | 2024 | |
| Adc Therapeutics America, INC. | $20.04 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $19.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.05 | 2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $18.86 | 2024 | Xpovio |
| Daiichi Sankyo INC. | $17.88 | 2024 | Enhertu |
| Eisai INC. | $16.96 | 2024 | |
| Taiho Oncology, INC. | $15.05 | 2025 | |
| Novocure INC. | $14.84 | 2019 | |
| Syndax Pharmaceuticals, INC. | $14.04 | 2025 | |
| Seagen INC. | $13.37 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Emandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.